Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026

Breakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond
/in Immunotherapy, mRNA, Preclinical Research/by MaxA groundbreaking study led by Stanford Medicine, published in Cancer Immunology Research, has introduced a revolutionary approach to generating chimeric antigen receptor (CAR)-T cells directly inside the body, offering a promising new avenue for cancer treatment. This “in situ” method, which uses mRNA delivered via lipid nanoparticles (LNPs), successfully treated B-cell lymphoma in mice and […]
How Exercise Boosts Cancer Immunotherapy: The Role of Gut Microbes and Formate
/in Not PCa related/by MaxNew Combination Therapy Gets Fast Tracked: 177Lu-PSMA-617 (Pluvicto) Plus TRE-515
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Dug Delivery Platform is Being Released
/in Delivery, Preclinical Research/by MaxNew Phase 3 Trial Approved for Masitinib for mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxKorean Team Unveils Breakthrough All-in-One Cancer Nanomedicine
/in Preclinical Research/by MaxIn a groundbreaking advancement for cancer treatment, a team from the Korea Research Institute of Standards and Science (KRISS) has developed an innovative nanomaterial that could transform cancer care. This “all-in-one” nanomedicine, known as gold-iron-gold nanodisks (AuFeAuNDs), integrates diagnosis, treatment, and immune activation into a single platform. Still in pre-clinical stages, this discovery shows significant […]
Early Results of Gedatolisib and Darolutamide in mCRPC Treatment
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMevrometostat Update: a New Phase 3 Trial for mCSPC
/in Clinical Trial, Metastatic, Phase 3/by Max